© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Renal Cell Carcinoma
Liquid Biopsy Shows High Accuracy in Detecting Early-Stage Renal Cell Carcinoma
June 24, 2020
If validated, the investigators believe that this non-invasive test could help detect renal cell carcinoma earlier on, thereby reducing the mortality of the disease.
Immunotherapy Regimens Reduce Toxicity in Advanced RCC Compared With Sunitinib
June 15, 2020
A pooled analysis of phase 3 clinical trials in advanced renal cell carcinoma showed that combination immunotherapy can reduce toxicity compared with sunitinib.
Phase 2 Trial Shows Antitumor Activity in Metastatic Clear Cell RCC
June 15, 2020
Chung-Han Lee, MD, PhD, discusses the efficacy of a phase 2 study of pembrolizumab and lenvatinib in patient with metastatic clear cell renal cell carcinoma who have progressed on an immune checkpoint inhibitor.
KEYNOTE-427 Brings Into Question Potential Biomarkers in Clear Cell Renal Cell Carcinoma
June 09, 2020
In an interview with Targeted Oncology, Scott Tykodi, MD, PhD, discussed findings from the analysis from the KEYNOTE-427 trial in patients with clear cell renal cell carcinoma.
Analyzing New Data from KEYNOTE-427 in Patients With RCC
June 08, 2020
Scott Tykodi, MD, PhD, discusses recent findings in the KEYNOTE-427 trial of pembrolizumab in patients with renal cell carcinoma.
Salvage Nivolumab/Ipilimumab Appears Promising in Clear Cell Renal Cell Carcinoma
June 04, 2020
“Nivolumab monotherapy represents an alternative frontline approach, particularly for the ipilimumab or VEGFR tyrosine kinase inhibitor averse and possible for those with IMDC favorable risk."
FDA Accepts NDA for Tivozanib in Relapsed/Refractory Renal Cell Carcinoma
June 01, 2020
"The acceptance of our NDA filing marks yet another important milestone for AVEO, as we pursue our goal of providing RCC patients whose disease has relapsed or become refractory to multiple lines of therapy with a meaningful new treatment option."
Survival Benefits Are Maintained With Frontline Pembrolizumab/Axitinib in Advanced RCC
May 30, 2020
Progression-free and overall survival in patients with previously untreated, advanced renal cell carcinoma continued to show improvements with the combination of pembrolizumab and axitinib versus sunitinib in the phase 3 KEYNOTE-426 trial.
Efficacy of Cabozantinib in Previously Treated RCC Is Consistent Irrespective of Prior Therapy
May 30, 2020
An analysis of patients with advanced renal cell carcinoma revealed that systemic therapy with cabozantinib induced reliable responses for patients regardless of whether or not they had received prior immunotherapy, according to data that were presented as part of the 2020 American Society of Clinical Oncology Virtual Scientific Program.
Novel MET Inhibitor Shows Encouraging Results in Papillary Renal Cell Carcinoma
May 29, 2020
"Although patient numbers and follow-up were limited, savolitinib demonstrated encouraging efficacy and an improved safety profile versus sunitinib."